Who
Jeffrey Chi
Director
Company insider
Files Form 4 as: Director, Aardvark Therapeutics.
In numbers
- Trades disclosed
- 5
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 14 Feb 2025
- Last trade
- 14 Aug 2026
- Last filed
- 21 Aug 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Aug 2026filed 21 Aug 2026 | AARD Aardvark Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,964 at $0.00 | filing |
| 14 Aug 2026filed 21 Aug 2026 | AARD Aardvark Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,964 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | AARD Aardvark Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —61,017 at $0.00 | filing |
| 14 Feb 2025filed 19 Feb 2025 | AARD Aardvark Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —1,130,135 at $0.00 | filing |
| 14 Feb 2025filed 19 Feb 2025 | AARD Aardvark TherapeuticsBiotechnology | SEC FORM 4 Code C | —133,364 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.